Nanjing Well Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.12%

Nanjing Well Pharmaceutical Co Ltd (603351) has an Asset Resilience Ratio of 0.12% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥3.00 Million
≈ $438.99K USD Cash + Short-term Investments

Total Assets

CN¥2.59 Billion
≈ $378.33 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2023)

This chart shows how Nanjing Well Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check how strategically is Nanjing Well Pharmaceutical Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Nanjing Well Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603351 market cap.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥3.00 Million 0.12%
Total Liquid Assets CN¥3.00 Million 0.12%

Asset Resilience Insights

  • Limited Liquidity: Nanjing Well Pharmaceutical Co Ltd maintains only 0.12% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Nanjing Well Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Nanjing Well Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
JW Pharmaceutical Corp
KO:001067
Drug Manufacturers - Specialty & Generic 8.17%
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275
Drug Manufacturers - Specialty & Generic 14.80%
Fuan Pharmaceutical Group Co
SHE:300194
Drug Manufacturers - Specialty & Generic 1.34%
DRI Healthcare Trust
TO:DHT-U
Drug Manufacturers - Specialty & Generic 13.91%
Hainan Shuangcheng Pharmaceut
SHE:002693
Drug Manufacturers - Specialty & Generic 1.03%

Annual Asset Resilience Ratio for Nanjing Well Pharmaceutical Co Ltd (2019–2023)

The table below shows the annual Asset Resilience Ratio data for Nanjing Well Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.05% CN¥1.25 Million
≈ $183.19K
CN¥2.28 Billion
≈ $333.48 Million
+0.00pp
2022-12-31 0.05% CN¥1.11 Million
≈ $161.86K
CN¥2.14 Billion
≈ $312.88 Million
-1.37pp
2021-12-31 1.42% CN¥26.24 Million
≈ $3.84 Million
CN¥1.84 Billion
≈ $269.46 Million
-10.60pp
2020-12-31 12.02% CN¥196.71 Million
≈ $28.78 Million
CN¥1.64 Billion
≈ $239.46 Million
+5.83pp
2019-12-31 6.19% CN¥90.31 Million
≈ $13.22 Million
CN¥1.46 Billion
≈ $213.39 Million
--
pp = percentage points

About Nanjing Well Pharmaceutical Co Ltd

SHG:603351 China Drug Manufacturers - Specialty & Generic
Market Cap
$494.09 Million
CN¥3.38 Billion CNY
Market Cap Rank
#12265 Global
#3553 in China
Share Price
CN¥24.93
Change (1 day)
+3.44%
52-Week Range
CN¥22.85 - CN¥32.52
All Time High
CN¥40.56
About

Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China. It is involved in the bio-based material manufacturing, sales, and technology development; technical development and consulting; bio-based material technology research and development; bi… Read more